Interim Chief Executive Officer

Mr. Duncan has more than 20 years of healthcare and life sciences experience including senior commercial, strategy and general management roles at GlaxoSmithKline, IVAX Pharmaceuticals, and Healthcare at Home. Prior to accepting the interim Chief Executive Officer role at Concordia International Corp., Mr. Duncan previously served as President of Concordia’s International segment since January 2016. Prior to his role as President, he was Managing Director for Concordia’s International segment.

David Price

Chief Financial Officer

Mr. Price brings more than 25 years of experience in the healthcare, investment banking and accounting industries to Concordia. Most recently, he served as CFO of Bioventus LLC, a private, equity-backed global provider of medical devices in the orthobiologics field. Prior to his role at Bioventus, Mr. Price was the CFO at EDGAR Online Inc., a financial data, technology and business process outsourcing company.  Prior to that, Mr. Price was CFO of Cornerstone Therapeutics, Inc., a publicly traded specialty pharmaceutical company. Mr. Price has previously served as managing director in the healthcare and pharmaceutical services sector at two investment banking firms – Jefferies & Company in New York, and Bear Stearns & Co. in London and New York – and worked at PricewaterhouseCoopers Consulting and Arthur Andersen. He holds an honors degree in Accounting and Financial Management from Lancaster University in the UK and is a member of the Institute of Chartered Accountants in England and Wales.

Guy Clark

Chief Corporate Development Officer

Mr. Clark brings to Concordia more than 25 years of experience in the pharmaceutical industry, including previous senior roles at Glenmark Pharmaceuticals and IVAX Pharmaceuticals. Most recently, Mr. Clark served as Chief Strategy Officer at AMCo Pharmaceuticals from 2013 to 2015. As Chief Corporate Development Officer for Concordia International Corp., Mr. Clark will focus on leading the Company’s corporate development initiatives including M&A, strategy formulation & implementation and expanding its pipeline of medicines.

Francesco Tallarico

Chief Legal Officer and Secretary

Mr. Tallarico is Chief Legal Officer and Secretary of Concordia International Corp. Mr. Tallarico manages the Global legal function of the Corporation. Prior to joining the Corporation in 2014, Mr. Tallarico practiced law at Fasken Martineau DuMoulin LLP, an international law firm based out of Toronto, Ontario, with a particular focus on corporate governance, corporate finance and M&A transactions. During his time with the Corporation, Mr. Tallarico has been actively involved and instrumental in various M&A transactions valued at over $4.5 billion. Mr. Tallarico holds a B.A. from the University of Toronto and a J.D. from the University of Windsor.

Sanjeeth Pai

President of Concordia North America

Mr. Pai has more than 25 years of experience in the healthcare industry including working across the value chains of medical device, pharma, pharmaceutical distribution and specialty pharma distribution companies. He spent the first part of his career working in operational and technical roles to manage the development, manufacture and launch of generic pharmaceutical products for companies including Abbott Laboratories, Wyeth and Actavis. Mr. Pai subsequently transitioned to a more commercial focus through a business development role in which he spent extensive time in Asia to seek portfolio opportunities for Alpharma’s U.S. market segment. Most recently, he held various general management roles leading pharmaceutical distribution and specialty pharma businesses for Cardinal Health.